PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Beijing Innocare Pharma Tech Co., Ltd.

USPTO PatentsView assignee record - 14 granted patents across 4 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Beijing ranks #19,501 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 4 technology areas.

#19,501
of 49,997 US assignees by volume
37th percentile
by Innovation Score (31.3/100)
8.1
avg claims per patent
+350%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19501 · Foreign Corporation #19,501 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,501/49,997
  • PHOTO-FINISH Behavioral Recogniti…
  • CPC-NARROW C07D · 4 areas
  • INNOV-THIN 31.3/100
  • CLAIMS-PAR 8.1 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +350% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Behavioral Recognition Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Beijing’s 31.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Beijing

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Beijing's Innovation Score is 31.3/100 (37th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Beijing?

Each dot is one of Beijing’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Beijing’s own 8.1 claims/patent is at or below the 15.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Beijing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 0510152025 Granted patents (volume) Avg claims / patent Behavioral Recognition Systems, Inc. - 14, 20.36Behavioral Recogn…Beijing ConST Instruments Technology Inc. - 14, 18.07Beijing Const Ins…Beijing Gridsum Technology Co., Ltd. - 14, 10.14Beijing Gridsum T…Beijing Huihaozi Technology Co., Ltd - 14, 1Beijing Huihaozi…Beijing Xiaoniao Tingting Technology Co., Ltd. - 14, 15.36Beijing Xiaoniao…Beijing Zhongxiangying Technology Co., Ltd. - 14, 15.36Beijing Zhongxian…Beijing information Science & Technology University - 14, 8.57Beijing informati…Bell and Howell, LLC - 14, 21.29Bell and HowellBeijing Innocare Pharma Tech Co., Ltd. - 14, 8.14Beijing Innocare…
Beijing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Beijing's grants concentrate

Beijing Innocare Pharma Tech Co., Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 92.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2018. By volume, Beijing sits between Behavioral Recognition Systems, Inc. and Bell and Howell, LLC.

Beijing's three-year grant acceleration

Beijing Innocare Pharma Tech Co., Ltd. shows 6 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Beijing's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Beijing holds 14 patents at rank #19,521, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Beijing

By rank, the assignees closest to #19,521 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Beijing's primary technology class.

Beijing's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 37th percentile higher than 37% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20182019202020212022202320242025 3
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Beijing Innocare Pharma Tech Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 1 7.1%
2019 1 7.1%
2020 1 7.1%
2021 2 14.3%
2022 1 7.1%
2023 2 14.3%
2024 3 21.4%
2025partial year 3 21.4%

Which technologies does Beijing Innocare Pharma Tech Co., Ltd. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Beijing Innocare Pharma Tech Co., Ltd.'s patent record in context - here's where to go next.

  • Beijing Innocare Pharma Tech Co., Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 92.9% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #19,501 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Beijing Innocare Pharma Tech Co., Ltd. against Behavioral Recognition Systems, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 31.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.